CLAIMS

1. A pharmaceutical composition in the form of a dry powder for inhalation comprising abediterol or a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable carrier, providing upon inhalation a dose equivalent to a metered nominal dose of 1.25 micrograms plus/minus 35% or 2.5 micrograms plus/minus 15% of free base abediterol administered with the Genuair® inhaler.

2. A pharmaceutical composition according to claim 1 in the form of a dry powder for inhalation comprising abediterol or a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable carrier, providing upon inhalation a metered nominal dose ranging from 0.81 to 1.69 micrograms, preferably from 0.93 to 1.57 micrograms, more preferably from 1.06 to 1.44 micrograms of free base abediterol.

3. A pharmaceutical composition according to claim 1 in the form of a dry powder for inhalation comprising abediterol or a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable carrier, providing upon inhalation a metered nominal dose ranging from 2.12 to 2.88 micrograms of free base abediterol.

4. A pharmaceutical composition according to claim 1 in the form of a dry powder for inhalation comprising abediterol or a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable carrier, providing upon inhalation a delivered dose ranging from 0.71 to 1.49 micrograms, preferably from 0.82 to 1.38 micrograms, more preferably from 0.93 to 1.27 micrograms of free base abediterol.

5. A pharmaceutical composition according to claim 1 in the form of a dry powder for inhalation comprising abediterol or a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable carrier, providing upon inhalation a delivered dose ranging from 1.95 to 2.65 of free base abediterol.

6. A pharmaceutical composition according to claim 1 in the form of a dry powder for inhalation comprising abediterol or a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable carrier, providing upon inhalation a fine particle dose ranging from 0.29 to 0.61 micrograms, preferably, from 0.33 to 0.57 micrograms being most preferably from 0.38 to 0.52 micrograms of free base abediterol, and having an aerodynamic particle diameter less than 5 micrometers.

7. A pharmaceutical composition according to claim 1 in the form of a dry powder for inhalation comprising abediterol or a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable carrier, providing upon inhalation a fine particle dose ranging from 0.85 to 1.15 micrograms of free base abediterol, and having an aerodynamic particle diameter less than 5 micrometers.

8. The pharmaceutical composition according to any of claims 1 to 7, in the form of a single-dose dry powder formulation comprising a single dose of abediterol as defined in any one of claims 1 to 7.

9. The pharmaceutical composition according to any of claims 1 to 7, in the form of a multi-dose dry powder formulation for administration in a mutlidose dry powder inhaler device calibrated to provide a dose of abediterol as defined in any one of claims 1 to 7.

10. The pharmaceutical composition according to any of claims 1 to 9, wherein the pharmaceutically acceptable salt is heminapadisylate.

11. The pharmaceutical composition according to any of claims 1 to 10, wherein the pharmaceutically acceptable carrier is lactose particles.

12. The pharmaceutical composition according to any of claims 1 to 11, wherein the ratio by weight of abediterol to carrier is from 1:1000 to 1:40000.

13. The pharmaceutical composition according to claim 12 wherein the ratio by weight of abediterol to carrier is from 1:2000 to 1:20000.

14. The pharmaceutical composition according to any of claims 1 to 13, wherein the average particle diameter of abediterol as an active agent is within 1.5-5 m.

15. The pharmaceutical composition according to any of claims 1 to 14, wherein the carrier particles have a d10 of 90 - 160 m, a d50 of 170 - 270 m, and d90 of 290 - 400 m.

16. The pharmaceutical composition according to claim 15, wherein the carrier particles are admixed with additional particles of lactose having a d10 of 2 - 4 m, a d50 of 7 - 10 m, and d90 of 15 - 24 m.

17. The pharmaceutical composition according to any of claims 1 to 16, further comprising an effective amount of one or more additional active agents selected from M3 antagonists, PDE IV inhibitors, and corticosteroids.

18. The pharmaceutical composition according to claim 17 wherein the additional active agent is selected from tiotropium, aclidinium, mometasone, fluticasone and roflumilast, in free or pharmaceutically acceptable salt form.

19. The pharmaceutical composition according to claim 17, wherein the additional active agent is mometasone furoate in a dose equivalent to a metered nominal dose of 50-900 micrograms administered with the Genuair® inhaler.

20. The pharmaceutical composition according to claim 19, wherein the mometasone furoate is present in an amount of 70 micrograms per metered nominal dose.

21. The pharmaceutical composition according to claim 19, wherein the mometasone furoate is present in an amount of 85 micrograms per metered nominal dose.

22. The pharmaceutical composition according to claim 19, wherein the mometasone furoate is present in an amount of 170 micrograms per metered nominal dose.

23. The pharmaceutical composition according to claim 19, wherein the mometasone furoate is present in an amount of 340 micrograms per metered nominal dose.

24. The use of abediterol in the manufacture of a medicament for treating a respiratory condition selected from asthma and chronic obstructive pulmonary comprising a pharmaceutical composition according to any of claims 1 to 23.

25. The use of abediterol in the manufacture of a medicament of claim 24 which is characterized as co-administrating with one or more additional active agents as defined in any of claims 17 to 23.

26. The use of abediterol in the manufacture of a pharmaceutical composition according to any of claims 1 to 23.